In this interview, Jesmond Dalli, PhD, focuses on effective therapeutic approaches for resolving joint inflammation and regeneration, while highlighting the shortcomings of some existing treatments. He details his latest research on the use of Maresins in treating rheumatoid arthritis patients and the clinical insights gained from this work. Dr. Dalli concludes by explaining how specialized pro-resolving mediators (SPMs) offer a novel approach to therapy and can complement standard pain management treatments. Jesmond Dalli, PhD, is a Professor of Molecular Pharmacology…

In this interview, Bruce Levy, MD discusses the most interesting research over the last few years, such as the development of mRNA vaccines, growth in cell-based therapies and expansion of interest in resolution biology. Dr. Levy describes the potential link between long COVID and dysregulation of resolution mediators and mechanisms. He further describes cytokine storm in this context. Dr. Levy also discusses the significance of external use of specialized pro-resolving mediators (SPMs) in resolving inflammation in some of the chronic…

In this interview, Gabrielle Fredman, PhD delves into the role of SPMs in aging. She elaborates on the research and potential of using specialized pro-resolving mediators (SPMs) endogenously as a preventative measure against aging. Additionally, Dr. Fredman discusses various internal factors involved in the resolution of inflammation and the mechanisms that might impede this process. She concludes by sharing her research findings on the connection of SPMs and atherosclerosis. Gabrielle Fredman, PhD, is an Associate Professor of Molecular and Cellular…

In this interview, Dipak Panigraphy, MD discusses cytokine storms in both COVID-19 and cancer patients, emphasizing their potential to disrupt resolution of inflammation and contribute to unfavorable clinical outcomes. Dr. Panigraphy discusses how standard cancer treatments, including surgery and chemotherapy, may trigger cytokine storms, facilitating the spread of cancer in some patients. Lastly, he discusses his latest research, demonstrating the efficacy of specific specialized pro-resolving mediators (SPMs) molecules in promoting inflammation resolution and preventing treatment-induced metastasis in multiple preclinical cancer…

Akkermansia muciniphila is a unique mucin-loving keystone species residing in the human gastrointestinal tract, purportedly offering health benefits, especially in the realms of metabolic health and obesity.1 Clinical investigations exploring A. muciniphila supplementation in overweight and obese cohorts seek to elucidate its potential impact on metabolic parameters, adiposity, and other health metrics. Studies consistently show reduced abundance in obesity, type 2 diabetes, high blood pressure, and other metabolic conditions.2 Intervention studies in animals demonstrated A. muciniphila administration reversed high-fat diet-induced metabolic disorders,…

by Kyle Perkovich, BS In the intricate ecosystem of the human gut, a new frontier is emerging, marked by the strategic paring of probiotics and prebiotics working synergistically to help provide optimal gut health and well-being. This combination, known as synbiotics, is gaining prominence for its potential to enhance gut health and immune function. As research has advanced, the role of our gut microbiota has become increasingly recognized as a vital part of overall health, influencing not only proper digestion,…

by Lewis Chang, PhD Not all heroes are muscle-bound and wear capes. There is a tiny, almost invisible, hero that lives in our gut and promotes our health and wellbeing. Its name, Akkermansia muciniphila, may be a mouthful, but it’s time to get to know this hero better, as its health-promoting effects have earned it the reputation as a next-generation beneficial bacteria.1 Gut health is intricately connected to human health in ways that surprise us. Our gut is home to…

We have compiled our most viewed blogs, webinars, and clinical tools on metabolic detoxification to help you keep up with the latest research on this topic that will enable you to help your patients’ live healthier, happier lives.

Angela Kelly, MA and Michael Stanclift, ND This is the last installment of a three-part series on bacterial vaginosis (BV). In part one, we discussed a healthy vaginal microbiome, symptoms, and diagnostic criteria. In part two , we highlighted the risk factors that contribute to BV, the health impacts it can cause, and conventional antimicrobial treatments, along with their propensity for resistance. As we saw in part two , conventional antimicrobials often only temporarily resolve BV, and contribute to antibiotic resistance. For…

Angela Kelly, MA and Michael Stanclift, ND This is part two in a three-part series about bacterial vaginosis (BV). In part one we discussed a healthy vaginal microbiome, BV’s characteristics, and diagnostic criteria. In this section, we’ll explore risk factors for developing BV, the health impacts of it, and current conventional therapies. BV risk factors While the precise causes of BV are still being investigated, researchers have discovered the following risk factors that can contribute to its development: Having a sexual…